Foghorn Therapeutics stock price target cut to $5 by H.C. Wainwright on program halt
H.C. Wainwright cut Foghorn Therapeutics' (FHTX) price target to $5 from $13 after it halted the FHD-909 program due to lack of efficacy. FHTX stock is down 16.57% this week. The company reduced its workforce by 40% and expects cash runway into 2H 2029. Multiple analysts downgraded FHTX, with price targets now ranging from $2 to $5.
How this was made
The 30-second read
Why it matters
The discontinuation of the FHD‑909 program removes a key collaboration with Eli Lilly, reducing future revenue potential and prompting analyst target cuts.
Market read
The news provides a fresh, material catalyst for FHTX, likely driving short‑term downside as investors reassess the pipeline.
What to watch
Potential cash‑runway extension to 2029 and solid current ratio may cushion short‑term sell‑off.
Background
Foghorn Therapeutics (FHTX) is a clinical‑stage biotech focused on epigenetic targets. The company recently reduced its workforce by ~40% and extended its cash runway.
Ticker impact
H.C. Wainwright cut FHTX price target to $5 after Foghorn halted its Lilly‑partnered FHD‑909 program following Phase 1 data.
likely pressure as investors price in the discontinued program and workforce reduction
Clinical‑trial halt is a material negative catalyst for a biotech; multiple analysts simultaneously lowered targets, indicating consensus on downside.
Market effects
May weigh on other SMARCA2/4 synthetic‑lethality programs and biotech peers with similar pipelines.
Limited to US‑listed biotech sector.
Low global impact; primarily affects FHTX and niche oncology investors.
Counterpoint
If the EP300/CBP pipeline shows early promise, the stock could rebound on future data.
Key entities
- companyFoghorn Therapeutics
Biotech developing synthetic‑lethal degraders.
- companyEli Lilly
Partner in the halted FHD‑909 program.
- analystH.C. Wainwright
Reduced price target to $5.
